GINA BOLINGER: Open Payments
NPI 1699849315 · THORNTON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,825 in 92 payments from 25 companies in 2025. Trend: 2023 $2,260 · 2024 $2,365 · 2025 $1,825
Food & beverage: $1,825
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $356 |
| AstraZeneca Pharmaceuticals LP | 13 | $351 |
| Novo Nordisk Inc | 7 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $103 |
| Abbott Laboratories | 5 | $101 |
| GlaxoSmithKline, LLC. | 4 | $98 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $95 |
| PFIZER INC. | 5 | $94 |
| Lilly USA, LLC | 3 | $61 |
| Seqirus USA Inc | 2 | $49 |
Products named: VRAYLAR, JARDIANCE, FARXIGA, BREZTRI, CAPLYTA, TRELEGY ELLIPTA, QULIPTA, Wegovy.
Industry payments across CO — which companies pay providers there.
